Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 4/20 | 0.55 |
| ▸ | PPARG | P37231 | 2/20 | 0.55 |
| ▸ | PPARD | Q03181 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | MMP8 | P22894 | 3/20 | 0.49 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | RECQL | P46063 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27908890 | 0.90 | SMN1; SMN2 (0.57) | PPARAPPARGPPARDSMN1; SMN2HIF1A | |
| SCHEMBL19183326 | 0.89 | PPARA (0.46) | PPARAPPARGPPARDSMN1; SMN2HIF1A | |
| SCHEMBL28755706 | 0.88 | PPARA (0.49) | PPARAPPARGPPARDSMN1; SMN2HIF1A | |
| SCHEMBL12268231 | 0.86 | RIPK1 (0.46) | PPARAPPARGPPARDSMN1; SMN2HIF1A | |
| SCHEMBL3159710 | 0.85 | SMN1; SMN2 (0.48) | PPARAPPARGPPARDSMN1; SMN2HIF1A | |
| SCHEMBL27490673 | 0.85 | BLM (0.61) | PPARAPPARGPPARD | |
| SCHEMBL11529482 | 0.85 | PPARA (0.49) | PPARAPPARGPPARDSMN1; SMN2MMP8 | |
| SCHEMBL29290738 | 0.85 | SMN1; SMN2 (0.48) | PPARAPPARGPPARDSMN1; SMN2HIF1A | |
| SCHEMBL3270827 | 0.83 | MMP8 (0.53) | PPARAPPARGPPARDSMN1; SMN2HIF1A | |
| SCHEMBL11527067 | 0.83 | PPARA (0.54) | PPARAPPARGPPARDSLC6A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9630989-B2 | Dipeptide analogs for treating conditions associated with amyloid fibril formation | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2017-04-25 | — | — | US | disclosed |
| US-9096645-B2 | Dipeptide analogs for treating conditions associated with amyloid fibril formation | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2015-08-04 | — | — | US | disclosed |
| US-8859777-B2 | 4-fluoro-4-arylpiperdin-1-yl derivatives as mu opioid function moderators | KINENTIA BIOSCIENCES LLC (US) | 2014-10-14 | — | — | US | disclosed |
| CN-103561732-A | Therapeutic compounds | ARKCIRIA PHARMACEUTICALS CO LTD | 2014-02-05 | — | — | CN | disclosed |
| US-20130045165-A1 | 4-FLUORO-4-ARYLPIPERDIN-1-YL DERIVATIVES AS MU OPIOID FUNCTION MODERATORS | KINENTIA BIOSCIENCES, LLC (US) | 2013-02-21 | — | — | US | disclosed |
| US-7812038-B2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| EP-1920042-B1 | PARTICLES CONTAINING PERFUME HAVING IMPROVED FRAGRANCED PROPERTIES | HENKEL AG & CO KGAA (DE) | 2010-06-23 | — | — | EP | disclosed |
| EP-2046929-A1 | LIQUID SUPPORT | Henkel AG & Co. KGaA (DE) | 2009-04-15 | — | — | EP | disclosed |
| EP-2038391-A1 | WASHING, CLEANING AND CARE PRODUCTS | Henkel AG & Co. KGaA (DE) | 2009-03-25 | — | — | EP | disclosed |
| WO-2008116509-A1 | CLEANING AGENT | HENKEL AG & CO. KGAA (DE) | 2008-10-02 | — | — | WO | disclosed |
| WO-1999009136-A1 | HIGH-DOSE FRAGRANCED SHAPED BODIES | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1999-02-25 | — | — | WO | disclosed |
| EP-0542348-B1 | Process for the preparation of phenylaldehydes | QUEST INT (NL) | 1997-06-18 | — | — | EP | disclosed |
| US-5358861-A | Oxidation of an unsaturated phenolic compound in the presence of the enzyme lipoxygenase; vanillin | UNILEVER PATENT HOLDINGS B.V. (NL) | 1994-10-25 | — | — | US | disclosed |
| EP-0406572-A1 | Cyclic compounds and their process of preparation | L. GIVAUDAN & CIE Société Anonyme (CH) | 1991-01-09 | — | — | EP | disclosed |
| EP-0330995-A2 | Bicyclic ethers | GIVAUDAN-ROURE (INTERNATIONAL) S.A. (CH) | 1989-09-06 | — | — | EP | disclosed |
| EP-0315895-A1 | Tricyclic compounds | L. GIVAUDAN & CIE Société Anonyme (CH) | 1989-05-17 | — | — | EP | disclosed |
| EP-0301375-A2 | Bicyclic aldehydes | L. GIVAUDAN & CIE Société Anonyme (CH) | 1989-02-01 | — | — | EP | disclosed |
| EP-0294746-A1 | Bicyclic nitro compounds | L. GIVAUDAN & CIE Société Anonyme (CH) | 1988-12-14 | — | — | EP | disclosed |
| EP-0195975-A2 | Bicyclic ketone, process for its preparation and odoriferous and/or aromatization compositions containing this bicyclic ketone | L. GIVAUDAN & CIE Société Anonyme (CH) | 1986-10-01 | — | — | EP | disclosed |
| US-4166131-A | ANTIINFLAMMATORY AGENTS, ANTIPYRETICS, ANTIARTHRITIC AGENT | HEXACHIMIE SOCIETE ANONYME (FR) | 1979-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045165-A1 | 4-FLUORO-4-ARYLPIPERDIN-1-YL DERIVATIVES AS MU OPIOID FUNCTION MODERATORS | OPRD1, OPRK1, OPRM1 | PPARA 153/4885PPARG 17/4885PPARD 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.